552331-49-4

Usage

Uses

Used in Organic Synthesis:
1-BOC-5-BROMO-INDAZOLE is used as a synthetic intermediate for the preparation of various organic compounds. Its bromine atom can be replaced with other functional groups through palladium-catalyzed cross-coupling reactions, enabling the synthesis of a wide range of molecules with diverse properties.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-BOC-5-BROMO-INDAZOLE is utilized as a key building block for the development of novel drug candidates. Its unique structure and the presence of the 1-BOC protecting group make it suitable for the synthesis of bioactive molecules with potential therapeutic applications.
Used in Material Science:
1-BOC-5-BROMO-INDAZOLE is employed in the field of material science for the design and synthesis of new materials with specific properties. The bromine atom in the compound can be used to introduce functional groups or to modify the electronic properties of the resulting materials, making them suitable for various applications, such as sensors, catalysts, or electronic devices.
Overall, 1-BOC-5-BROMO-INDAZOLE is a versatile chemical compound with a broad range of applications in organic synthesis, pharmaceutical research, and material science, owing to its unique structure and the presence of the 1-BOC protecting group.

InChI:InChI=1/C12H13BrN2O2/c1-12(2,3)17-11(16)15-10-5-4-9(13)6-8(10)7-14-15/h4-7H,1-3H3

Upstream product

• 552331-16-5 5-bromo-3-methyl-1H-indazole 
• 24424-99-5 di-tert-butyl dicarbonate 
• 34619-03-9 tert-butyldicarbonate 
• 198477-89-3 1-(5-bromo-2-fluorophenyl)ethan-1-one 
• 552331-15-4 1-(5-bromo-2-fluorophenyl)ethan-1-ol 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 

Downstream Products

• 267875-55-8 3-methyl-1H-indazole-5-carbonitrile 
• 1015068-77-5 tert-butyl 5-cyano-3-methyl-1H-indazolecarboxylate 

Relevant academic research and scientific papers

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

A is ATP competitive small molecule AKT inhibitor A443654 synthetic method

The invention discloses a synthesis method of an ATP competitive small-molecule AKT inhibitor A443654. According to the method, a compound 1 is used as a starting raw material, and the compound 6 (A-443654) is obtained through amino group protection, Suzuki reaction and protecting group removal. Usage of poisonous reagent hexamethylditin is avoided, the method is high in safety, environment-friendly, high in reaction yield and suitable for industrial large-scale production, the reaction time is shortened, and the process cost is reduced. The flow chart of the synthesis method is shown in the specification.

Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer

A novel series of pyridin-3-amine derivatives were designed, synthesized, and evaluated as multitargeted protein kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC). Hit 1 was first disclosed by in silico screening against fibroblast

2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE

The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.

FUSED HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF MALARIA

A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein: R1 is -NR3R4 or -OR5; R2 is selected from aryl, heteroaryl, fused aryl- heterocycloalkyl and fused heteroaryl-heterocycloalkyl each of which may be optionally substituted by one or more R8 groups; R3 is H or alkyl; R4 is: (i) cycloalkyl optionally substituted by one or more -NR11R12, -NHCO2R11, -NHCOR11 and -NHSO2R11 groups; or (ii) -(CH2)n-heterocycloalkyl, wherein said heterocycloalkyl is a 4, 5 or 6-membered nitrogen-containing group optionally containing one or more CO groups, wherein said heterocycloalkyl is optionally substituted by one or more one or more (CH2)nR7 groups; (iii) -(CH2)n-heteroaryl, wherein said heteroaryl group is optionally substituted by one or more R7 groups; or (iv) alkyl substituted by one or more -NR11R12groups; or R3 and R4 are linked together with the nitrogen to which they are attached to form a 4, 5 or 6-membered heterocycloalkyl group optionally containing one or two further groups selected from CO, O, N and S, and which is optionally further substituted by one or more R7 groups; R5 is selected from alkyl, -(CH2)n-heteroaryl and -(CH2)n-heterocycloalkyl, wherein said heteroaryl and heterocycloalkyl groups are each optionally substituted by one or more R7 groups; each R11 and R12 is independently H or alkyl; and each n is independently an integer from O to 6; for use in treating or preventing a disorder associated with CDPK. Further aspects relate to the use of said compounds in the treatment of various therapeutic disorders, and more particularly as inhibitors of PfCDPK1.

Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Provided herein are Heterocyclic Compounds having the following structure: wherein R1, R2, X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.

6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS

Methods for using 6-aminoimidazo[1,2-b]pyridazine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of 6-aminoimidazo[1,2-b]pyridazine analogs, are disclosed herein.

5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

Kinase inhibitors

Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.

Kinase inhibitors

Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.